Drug-eluting Stent Thrombosis: Current and Future Perspectives

Overview

Journal Cardiovasc Interv Ther

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2021 Jan 13

PMID 33439454

Citations 33

Authors

Shoichi Kuramitsu

Shinjo Sonoda

Kenji Ando

Hiromasa Otake

Masahiro Natsuaki

Reo Anai

Yasuhiro Honda

Kazushige Kadota

Yoshio Kobayashi

Takeshi Kimura

Affiliations

Soon will be listed here.

Abstract

Over the past 40 years, the safety and efficacy of percutaneous coronary intervention has dramatically improved by overcoming several challenges. The introduction of drug-eluting stent (DES) in particular was a major breakthrough in interventional cardiology. Compared to bare-metal stents, first-generation DES (G1-DES) has dramatically reduced the rates of in-stent restenosis and subsequent target lesion revascularization. However, major safety concerns surrounding stent thrombosis (ST) emerged with G1-DES in clinical practice as a result of the high incidences of death, myocardial infarction, and repeat revascularization associated with ST. To overcome these limitations, second-generation DES (G2-DES) has been developed with an improved stent platform with thinner strut and biocompatible durable or biodegradable polymers. Indeed, G2-DES, when compared with G1-DES, has improved clinical outcomes by reducing the risk of late thrombotic events while maintaining anti-restenotic efficacy, whereas ST still occurs, even with the use of G2-DES. This review gives an overview of pathophysiology, risk factors, and outcomes of ST after DES implantation. Additionally, we discuss the management and prevention of ST.

Citing Articles

Drug Loss at Arterial Bends Can Dominate Off-Target Drug Delivery by Paclitaxel-Coated Balloons.

Tscheuschner L, Stratakos E, Kostakis M, Gravanis M, Katsimpoulas M, Pennati G Pharmaceutics. 2025; 17(2).

PMID: 40006564 PMC: 11858837. DOI: 10.3390/pharmaceutics17020197.

Platelets, Biomarkers of Coagulation and Fibrinolysis, and Early Coronary Stent Thrombosis.

Galli L, Sator A, Schauer S, Brau K, Bernhard J, Hengstenberg C J Clin Med. 2025; 14(1.

PMID: 39797139 PMC: 11721602. DOI: 10.3390/jcm14010056.

Off-pump coronary artery bypass grafting versus percutaneous coronary intervention with second-generation drug-eluting stents for coronary artery revascularization.

Li N, Xiong X, Yang K, Xu Y, Chen Z, Liu P J Int Med Res. 2024; 52(12):3000605241304545.

PMID: 39711165 PMC: 11672580. DOI: 10.1177/03000605241304545.

Coronary artery bypass grafting drug-eluting stent implantation: the probabilities of reintervention, transition to severe care-need, nursing home, and death in patients with coronary artery disease within the first three years: evaluations based....

Georges D, Kreft D, Doblhammer G J Thorac Dis. 2024; 16(8):4863-4874.

PMID: 39268109 PMC: 11388224. DOI: 10.21037/jtd-24-251.

Innovative nomogram for predicting 1-year clinically driven revascularization outcomes in endovascular femoropopliteal disease.

Pan D, Wu S, Wang H, Ning Y, Guo J, Wang C Front Cardiovasc Med. 2024; 11:1438214.

PMID: 39263530 PMC: 11387798. DOI: 10.3389/fcvm.2024.1438214.

References

Morice M, Serruys P, Sousa J, Fajadet J, Ban Hayashi E, Perin M . A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346(23):1773-80. DOI: 10.1056/NEJMoa012843. View

van Werkum J, Heestermans A, de Korte F, Kelder J, Suttorp M, Rensing B . Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation. 2009; 119(6):828-34. DOI: 10.1161/CIRCULATIONAHA.108.799403. View

Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T . Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and.... Circulation. 2010; 122(1):52-61. DOI: 10.1161/CIRCULATIONAHA.109.903955. View

Galloe A, Kelbaek H, Thuesen L, Hansen H, Ravkilde J, Hansen P . 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. J Am Coll Cardiol. 2017; 69(6):616-624. DOI: 10.1016/j.jacc.2016.11.055. View

Tada T, Byrne R, Simunovic I, King L, Cassese S, Joner M . Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013; 6(12):1267-74. DOI: 10.1016/j.jcin.2013.06.015. View

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Valgimigli M . Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013; 62(6):496-504. DOI: 10.1016/j.jacc.2013.05.022. View

Philip F, Agarwal S, Bunte M, Bunte M, Goel S, Tuzcu E . Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: network meta-analysis of primary percutaneous coronary intervention trials in ST-segment–elevation myocardial infarction [corrected]. Circ Cardiovasc Interv. 2013; 7(1):49-61. DOI: 10.1161/CIRCINTERVENTIONS.113.000412. View

Cutlip D, Windecker S, Mehran R, Boam A, Cohen D, van Es G . Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17):2344-51. DOI: 10.1161/CIRCULATIONAHA.106.685313. View

Holmes Jr D, Kereiakes D, Garg S, Serruys P, Dehmer G, Ellis S . Stent thrombosis. J Am Coll Cardiol. 2010; 56(17):1357-65. DOI: 10.1016/j.jacc.2010.07.016. View

10.

Claessen B, Henriques J, Jaffer F, Mehran R, Piek J, Dangas G . Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv. 2014; 7(10):1081-92. DOI: 10.1016/j.jcin.2014.05.016. View

11.

Torrado J, Buckley L, Duran A, Trujillo P, Toldo S, Valle Raleigh J . Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis. J Am Coll Cardiol. 2018; 71(15):1676-1695. DOI: 10.1016/j.jacc.2018.02.023. View

12.

Kuramitsu S, Iwabuchi M, Haraguchi T, Domei T, Nagae A, Hyodo M . Incidence and clinical impact of stent fracture after everolimus-eluting stent implantation. Circ Cardiovasc Interv. 2012; 5(5):663-71. DOI: 10.1161/CIRCINTERVENTIONS.112.969238. View

13.

Kuramitsu S, Ohya M, Shinozaki T, Otake H, Horie K, Kawamoto H . Risk Factors and Long-Term Clinical Outcomes of Second-Generation Drug-Eluting Stent Thrombosis. Circ Cardiovasc Interv. 2019; 12(6):e007822. DOI: 10.1161/CIRCINTERVENTIONS.119.007822. View

14.

Cayla G, Hulot J, OConnor S, Pathak A, Scott S, Gruel Y . Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011; 306(16):1765-74. DOI: 10.1001/jama.2011.1529. View

15.

Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T . Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation. 2011; 125(4):584-91. DOI: 10.1161/CIRCULATIONAHA.111.046599. View

16.

Fujii K, Carlier S, Mintz G, Yang Y, Moussa I, Weisz G . Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol. 2005; 45(7):995-8. DOI: 10.1016/j.jacc.2004.12.066. View

17.

Choi S, Witzenbichler B, Maehara A, Lansky A, Guagliumi G, Brodie B . Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. Circ Cardiovasc Interv. 2011; 4(3):239-47. DOI: 10.1161/CIRCINTERVENTIONS.110.959791. View

18.

DAscenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez J . Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2012; 167(2):575-84. DOI: 10.1016/j.ijcard.2012.01.080. View

19.

Sarno G, Lagerqvist B, Nilsson J, Frobert O, Hambraeus K, Varenhorst C . Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol. 2014; 64(1):16-24. DOI: 10.1016/j.jacc.2014.04.022. View

20.

Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi G, Stankovic G . Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293(17):2126-30. DOI: 10.1001/jama.293.17.2126. View